Markets
markets
Luke Kawa

Bank of America more than doubled its price target on CoreWeave and... downgraded the stock

I’ve been doing this writing-about-stocks thing for a while, and cannot remember ever seeing something quite like this:

Bank of America analysts hiked their price target on CoreWeave by 143%, to $185 from $76, while simultaneously cutting their rating on the stock to “neutral” from “buy.”

That $185 price target is by far the highest on Wall Street. None of the analysts with a “buy” rating on the stock have updated their price targets since June 3; most haven’t since mid-May.

At its essence, this is a strict valuation call by Bank of America.

“We acknowledge there are positive developments including: (1) a new hyperscaler customer; (2) expansion on OpenAI agreement; and (3) debt raise at lower cost of capital,” analyst Brad Sills wrote. “As such, we raise our price objective to $185 from $76. However, with stock trading at 25x CY27e EBIT, a premium to the peer group at 16x, we believe much of the upside is priced in.”

Kudos to Sills for actually marking views to the new market realities, unlike most of his peers.

While CoreWeave recently raised debt at an incrementally lower interest rate, its significant capex plans mean the company will need to raise much more in the future, per Sills, who believes “the AI infrastructure capex growth rate is peaking” overall.

The recently IPO’d cloud computing company has become a new favorite of retail investors, particularly in the options market, and its supply is currently artificially suppressed. Per Bloomberg, a little under 13% of shares outstanding are available to be traded (or part of the “float,” as it’s known) in light of post-IPO lockup restrictions on selling.

More Markets

See all Markets
markets

Moderna jumps after settling Covid vaccine patent dispute

Moderna is up 4.8% at 5 a.m. ET in premarket trading after the pharma giant said on Tuesday that it had reached a deal to resolve a patent dispute related to the technology behind key Covid vaccine models.

Moderna will pay $950 million upfront, and a further $1.3 billion down the line, depending on the result of a separate appeal, to Arbutus Biopharma and Genevant Sciences to resolve all related disputes across its Spikevax® and mRESVIA® models. The settlement comes with no further royalties, which the company said in a press release would provide “certainty going forward for Moderna's full infectious disease portfolio.” That said, if Moderna’s appeal, based on its government-contractor immunity defense limits, ultimately prevails, the two biotech companies will refund the payment in full, including interest.

The $950 million charge is expected to be recorded in Q1 2026, per the company’s press release, leading Moderna to adjust its cash and cash equivalents expectations in the current calendar year to fall between $4.5 and $5 billion. Still, as analysts at William Blair observed late Tuesday, the total settlement amount is “worse than feared” — a take investors seem to be getting onboard with.

Noting that Moderna is driving towards its goal to break even in 2028, CEO Stéphane Bancel commented: “resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future.”

markets

Oil to lows and stocks to highs of day after President Trump says US will insure and escort oil tankers through the Gulf

West Texas Intermediate futures dipped to their lowest level of the day while the SPDR S&P 500 ETF continued to pare losses after US President Donald Trump ordered immediate action to improve the flow of oil to global markets, as the US-Iran conflict caused shipments through the Strait of Hormuz to slow to a crawl.

In a Truth Social post, the president said the US International Development Finance Corp. would provide “political risk insurance and guarantees for the Financial Security of ALL Maritime Trade, especially Energy, traveling through the Gulf,” adding that the US Navy would escort tankers through the Strait of Hormuz as soon as possible, if necessary.

Bloomberg’s Javier Blas explained that having oil-producing countries in the region able to reload crude on tankers is critical to avoiding production shut-ins.

Of course, there is a risk of unintended consequences from a heightened US presence in the region’s most strategically important area, from the perspective of global markets, during a time of kinetic military action. US naval escorts through the strait could dramatically increase the risk of an incident that massively escalates the conflict.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.